AbbVie agrees to buy immunology biotech Apogee Therapeutics for $10.9 billion
CNBC—AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, a major bet on next-generation immunology drugs as the pharma giant looks to expand beyond its flagship Humira franchise. The deal deepens AbbVie's pipeline in a competitive therapeutic area targeting conditions such as atopic dermatitis and asthma.
- CNBC — AbbVie bets $10.9B on next-generation immunology to expand beyond Humira
- Financial Times — AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
- Wall Street Journal — AbbVie agrees to buy immunology drug developer Apogee Therapeutics for $10.9 billion
- Reuters — AbbVie acquires next-generation immunology biotech Apogee Therapeutics for $10.9 billion
- Google News Top — Deal deepens AbbVie's pipeline in atopic dermatitis and asthma treatments